News by subject: TRI

Aifred Health, an award-winning digital healthcare company, today announced the conclusion of its North American Clinical Trial and initiation of the preparation of regulatory filings to seek US and Canadian approval for its novel AI-driven clinical...

Advarra, the market leader in regulatory review solutions and clinical research technology for sites and sponsors, announced a new site-specific eConsent module in the Advarra clinical trial technology portfolio. The integrated solution extends the...

USPTO issues new patent covering Talicia[1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI)[2], supporting Talicia protection until May 2042 The patent is supported by previously published pooled data from two Phase...

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the...

Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide,...

New study results from the COSMOS trial offers additional evidence regarding the benefit of Centrum Silver multivitamins on cognitive health in older adults. The third independent cognition trial to measure cognitive function and memory in older...

The U.S. Food and Drug Administration has placed a purchase order (75F40123P00369) committing to an annual subscription of digiM I2S, a fully integrated image processing platform based on digiM's proprietary cloud technology. I2S, short for Image to...

? MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment ? MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Protocol CR rate of 46% plus a CR/CRi rate of 54%...

Actinogen Medical Limited announces that its human Positron Emission Tomography (PET) study, confirming high levels of Xanamem target occupancy in the brain at safe, well tolerated, and biologically active doses, has been published in the Journal of...

Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced that the first healthy subject has been dosed in a Phase 1 clinical...

Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium (San Francisco,...

Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in microbiome therapeutic development announced on January 18th (local time) that a poster was presented on the positive topline results from the phase 2 clinical trial (NCT05419362)...

Endo International plc announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study.1 Consensus-based study findings...

A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to...

Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BSI-082, a novel anti-SIRP? monoclonal...

The fountain of youth has eluded explorers for ages. It turns out the magic anti-aging elixir might have been inside us all along....

Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced today the Company...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University. This Phase III...

Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in microbiome therapeutic development announced on January 18th that a poster was presented on the positive topline results from the phase 2 clinical trial (NCT05419362) in gastric...

STOCKHOLM, Jan. 24, 2024 /PRNewswire/ -- Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day,...

Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class...

Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) of the United States to initiate the first-in-human (FIH) clinical...

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced today the initiation of patient dosing in the Phase 1a/b clinical trial of...

Sciwind Biosciences...

A ribbon of brain tissue called cortical gray matter grows thinner in people who go on to develop dementia, and this appears to be an accurate biomarker of the disease five to 10 years before symptoms appear, researchers from The University of Texas...

The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the development of antiviral treatments to help protect the world ahead of future pandemics, today published the first phase of its global...

Quest PharmaTech Inc. ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received information that the...

Children's Hospital of Philadelphia (CHOP) is proud to announce the initial results of an experimental gene therapy treatment of a patient with hereditary hearing loss in the United States. Findings to date indicate that the treatment was successful....

Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company , today announced...

Taiho Oncology, Inc. announces publication of the final results from the pivotal ASCERTAIN clinical trial of fixed-dose oral decitabine and cedazuridine (INQOVI®) compared to intravenous decitabine in adults with intermediate and high-risk...

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly...

Complion, LLC, a leader in eRegulatory solutions (eReg and eISF) for clinical trials, is teaming up with a world-renowned pediatric research center. This collaboration signifies a notable achievement for Complion, a RealTime Software Solutions...

Enable Biosciences Inc. is proud to announce the enhancement of its 'Kit to Clinics' program for type 1 diabetes care, featuring the ADAP (Antibody Detection by Agglutination-PCR) technology, rigorously and exhaustively vetted through multiple...

Viscient Biosciences ("Viscient") today announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of...

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the...

Neuromod Devices Ltd., developer of the first and only FDA approved bimodal neuromodulation tinnitus treatment device, Lenire®, has announced reorganisation of the company's finance responsibilities within its Senior Management Team. The...

Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment...

Health Canada has authorized Jardiance® (empagliflozin) to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular and renal death in adults with chronic kidney disease (CKD),1 Boehringer Ingelheim (Canada) Ltd. and Eli...

CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat...

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , announced its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug...

Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...

New paper in The Lancet Neurology proposes the first iteration of a research framework for defining and staging Parkinson's disease (PD) based on biology, rather than clinical symptomsThe framework defines PD based on the neuronal alpha-synuclein...

Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514...

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis -  Primary efficacy endpoints: NASH resolution without worsening of...

In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion. The foreign patient was first diagnosed with...

Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with...

Haystack Oncology, a Quest Diagnostics company and developer of best-in-class personalized MRD technology (Haystack MRDtm), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular...

Data illustrates rapid and significant clearance in moderate to severe scalp psoriasis and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory pigmentation at 16...

INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside...

Meru Health, a technology-enabled digital mental health provider with a novel mind-body approach to mental healthcare, published a randomized controlled trial in collaboration with Stanford University, Harvard University, and University of Louisville...